BioCentury | Apr 15, 2013
Company News

VLST cancer, autoimmune, inflammation news

...New York, N.Y.) in August. The anti- CD40 mAb has completed five Phase I trials. VLST...
..."probably" start in pancreatic cancer (see BioCentury, Sept. 3). VLST also said it has licensed VLST-007...
...compounds are in preclinical development for autoimmune and inflammation indications. VLST declined to disclose details. VLST Corp....
BioCentury | Sep 3, 2012
Company News

VLST, Pfizer deal

...cancer vaccine field. VLST declined to provide financial details, while Pfizer could not be reached. VLST...
...for $55 million. VLST Corp. , Seattle, Wash. Pfizer Inc. (NYSE:PFE), New York, N.Y. Pfizer granted VLST...
...the company's first foray into cancer. VLST's pipeline also includes preclinical autoimmune and inflammation products: VLST-007...
BioCentury | Aug 31, 2012
Company News

VLST in-licenses Pfizer's anti-CD40 mAb

...Pfizer Inc. (NYSE:PFE) granted VLST Corp. (Seattle, Wash.) worldwide rights to cancer compound CP-870,893 . The anti...
...the company's first foray into cancer. VLST's pipeline also includes preclinical autoimmune and inflammation products: VLST-007...
...fused to the Fc portion of a human IgG1 molecule, and VLST-002, an anti-chemokine antibody. VLST...
BioCentury | May 28, 2012
Finance

Pressing the Accelerator

...Five of the Accelerator companies have raised series B rounds, including autoimmune and inflammation play VLST Corp....
BioCentury | Sep 6, 2010
Company News

Oncothyreon management update

...CFO and VP of corporate development, formerly CFO and VP of finance and operations of VLST Corp. WIR...
BioCentury | Apr 19, 2010
Company News

Anaptys, VLST deal

...its somatic hypermutation technology to generate antibodies against undisclosed autoimmune and inflammatory targets for VLST. VLST...
...upfront payment and is eligible for milestones and royalties. AnaptysBio Inc. , San Diego, Calif. VLST Corp....
BioCentury | Dec 22, 2008
Company News

VLST, Novo Nordisk deal

...will use VLST's discovery platform to identify targets and biologics for autoimmune and inflammatory disorders. VLST...
...payment and a $12 million equity investment from Novo, plus research funding for three years. VLST...
...biologics not selected by Novo. VLST's platform combines bioinformatics and proteomics to identify biologic targets. VLST Corp....
BioCentury | Nov 17, 2008
Finance

Ebb & Flow

...last five years, Accelerator has invested in nine early-stage biotechs, including autoimmune and inflammation company VLST...
BioCentury | Jul 7, 2008
Company News

VLST management update

VLST Corp. , Seattle, Wash. Business: Autoimmune, Inflammation Hired: Paul Carter as CSO and SVP of research and development, formerly VP of antibody technologies at Seattle Genetics Inc. WIR Staff...
BioCentury | Oct 29, 2007
Finance

Ebb & Flow

...Aug. 6) . Substantial B rounds also have gone to previous Accelerator graduates: cancer play VLST...
Items per page:
1 - 10 of 20
BioCentury | Apr 15, 2013
Company News

VLST cancer, autoimmune, inflammation news

...New York, N.Y.) in August. The anti- CD40 mAb has completed five Phase I trials. VLST...
..."probably" start in pancreatic cancer (see BioCentury, Sept. 3). VLST also said it has licensed VLST-007...
...compounds are in preclinical development for autoimmune and inflammation indications. VLST declined to disclose details. VLST Corp....
BioCentury | Sep 3, 2012
Company News

VLST, Pfizer deal

...cancer vaccine field. VLST declined to provide financial details, while Pfizer could not be reached. VLST...
...for $55 million. VLST Corp. , Seattle, Wash. Pfizer Inc. (NYSE:PFE), New York, N.Y. Pfizer granted VLST...
...the company's first foray into cancer. VLST's pipeline also includes preclinical autoimmune and inflammation products: VLST-007...
BioCentury | Aug 31, 2012
Company News

VLST in-licenses Pfizer's anti-CD40 mAb

...Pfizer Inc. (NYSE:PFE) granted VLST Corp. (Seattle, Wash.) worldwide rights to cancer compound CP-870,893 . The anti...
...the company's first foray into cancer. VLST's pipeline also includes preclinical autoimmune and inflammation products: VLST-007...
...fused to the Fc portion of a human IgG1 molecule, and VLST-002, an anti-chemokine antibody. VLST...
BioCentury | May 28, 2012
Finance

Pressing the Accelerator

...Five of the Accelerator companies have raised series B rounds, including autoimmune and inflammation play VLST Corp....
BioCentury | Sep 6, 2010
Company News

Oncothyreon management update

...CFO and VP of corporate development, formerly CFO and VP of finance and operations of VLST Corp. WIR...
BioCentury | Apr 19, 2010
Company News

Anaptys, VLST deal

...its somatic hypermutation technology to generate antibodies against undisclosed autoimmune and inflammatory targets for VLST. VLST...
...upfront payment and is eligible for milestones and royalties. AnaptysBio Inc. , San Diego, Calif. VLST Corp....
BioCentury | Dec 22, 2008
Company News

VLST, Novo Nordisk deal

...will use VLST's discovery platform to identify targets and biologics for autoimmune and inflammatory disorders. VLST...
...payment and a $12 million equity investment from Novo, plus research funding for three years. VLST...
...biologics not selected by Novo. VLST's platform combines bioinformatics and proteomics to identify biologic targets. VLST Corp....
BioCentury | Nov 17, 2008
Finance

Ebb & Flow

...last five years, Accelerator has invested in nine early-stage biotechs, including autoimmune and inflammation company VLST...
BioCentury | Jul 7, 2008
Company News

VLST management update

VLST Corp. , Seattle, Wash. Business: Autoimmune, Inflammation Hired: Paul Carter as CSO and SVP of research and development, formerly VP of antibody technologies at Seattle Genetics Inc. WIR Staff...
BioCentury | Oct 29, 2007
Finance

Ebb & Flow

...Aug. 6) . Substantial B rounds also have gone to previous Accelerator graduates: cancer play VLST...
Items per page:
1 - 10 of 20